In addition, although the differences in IC50 values of erlotinib and bortezomib between the two groups were not statistically significant, the scatter plots revealed a clear trend of increasing or decreasing IC50 values corresponding to the risk scores (Fig. 7 I–J).
← all excerpts
Development and validation of a novel disulfidptosis-related gene signature for prediction of survival and immune microenvironment in osteosarcoma by WGCNA analysis.
1
—
—